Equillium, Inc. — fact timeline

Equillium, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. at the 2026-05-28 meeting.

“Proposal 4. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,687,545 11,570,307 29,477 0”

Equillium, Inc. shareholders approved Ratification of the appointment of the independent registered public accounting firm. at the 2026-05-28 meeting.

“Proposal 3. Ratification of the appointment of the independent registered public accounting firm. The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 54,274,675 5,234 7,420 0”

Equillium, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split. at the 2026-05-28 meeting.

“Proposal 2. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 52,697,618 1,559,976 29,735 0”

Equillium, Inc. shareholders approved Election of directors. at the 2026-05-28 meeting.

“Proposal 1. Election of directors. The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. Former director Peter Colabuono was not renominated as a director and his term ended at the Annual Meeting. In connection with the expiration of Mr. Colabuono’s term, the Company reduced the size of the Board of Directors from seven directors to six directors. The final voting results are as follows: Name Votes For Votes Withheld Broker Non- Votes Charles McDermott 36,072,238 10,018,889 8,196,202 Bruce Steel 45,955,052 136,075 8,196,202”

Equillium, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $5.3 million, or $(0.06) per basic and diluted share, EPS $(0.06) per basic and diluted share.

“On May 13, 2026, Equillium, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026”

Equillium, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.

“On March 25, 2026, Equillium, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”

Equillium, Inc. issued pre-funded warrant to purchase up to 17,698,593 Warrant Shares at $0.0001 exercise price of warrant to RA Capital Healthcare Fund, L.P. for purchase price of $1.8539 per Warrant Share.

“a pre-funded warrant to purchase up to 17,698,593 Warrant Shares at a purchase price of $1.8539 per Warrant Share (the “Warrant Price”) to the Investor for gross proceeds to the Company of approximately $35.0 million.”

Equillium, Inc. issued 1,179,508 Shares at $1.854 per share of common stock to RA Capital Healthcare Fund, L.P. for gross proceeds of approximately $35.0 million.

“up to 17,698,593 Warrant Shares at a purchase price of $1.8539 per Warrant Share (the “Warrant Price”) to the Investor for gross proceeds to the Company of approximately $35.0 million. The pre-funded warrant will have an exercise price of $0.0001 per Warrant Share, subject to customary adjustments, and will be exercisable at any time after original issuance”

Equillium, Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. valued at approximately $35.0 million (effective 2026-03-11).

“On March 11, 2026, Equillium, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Healthcare Fund, L.P. (the “Investor”), pursuant to which the Company agreed to sell and issue shares (“Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and a pre-funded warrant to purchase shares of Common Stock (“Warrant Shares”), in a private placement transaction (the “Private Placement”).”

Equillium, Inc. engaged Crowe LLP as its auditor.

“On October 21, 2025, Crowe confirmed that such client acceptance procedures were complete, and the Company and Crowe executed an engagement letter to engage Crowe as the Company's independent registered public accounting firm.”

Equillium, Inc. engaged Crowe LLP as its auditor.

“On September 30, 2025, the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to the execution of an engagement letter and completion of Crowe’s standard client acceptance procedures.”

Equillium, Inc. dismissed KPMG LLP as its auditor.

“On September 30, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Equillium, Inc. (the “Company”) approved dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on September 30, 2025.”

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 13, 2024, Equillium, Inc. (the “ Company ” ) received a notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). The Company was given 180 days, or until June 11, 2025, to regain compliance with the Minimum Bid Price Requirement. On June 12, 2025, the Company received a notice from Nasdaq that the Company was granted an additional 180 calen”

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 13, 2024, Equillium, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and the Company’s common stock continues to trade on the Nasdaq Capital Market under the symbol “EQ.” Under Nasda”

Equillium, Inc. reported the first quarter ended March 31, 2024 results: revenue $10.7 million, net income $2.7 million, EPS $(0.08) per basic and diluted share.

“1 Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time of payment. Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023. Revenue in the first quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of”

Equillium, Inc. reported the fourth quarter and full year 2023 results: revenue $9.2 million.

“Revenue for the fourth quarter of 2023 was $9.2 million”

Penny Tom was appointed as principal accounting officer at Equillium, Inc..

“On March 6, 2024, the Board of Directors (the “Board”) of Equillium, Inc. (the “Company”) appointed Penny Tom, the Company’s Senior Vice President, Finance, as the Company’s principal accounting officer (to replace Jason Keyes, the Company’s Chief Financial Officer, in such role).”

Equillium, Inc. terminated "Prior Agreement" with Jefferies LLC (effective 2023-10-05).

“On October 5, 2023, the Company and Jefferies terminated that certain Open Market Sale Agreement SM (the " Prior Agreement ") that the Company entered into with Jefferies on July 14, 2020.”

Equillium, Inc. entered into "Sale Agreement" with Jefferies LLC (effective 2023-10-05).

“On October 5, 2023, Equillium, Inc. (the " Company ") entered into an Open Market Sale Agreement SM (the " Sale Agreement ") with Jefferies LLC (" Jefferies "), pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.0001 per share (the " Shares "), through Jefferies, as the Company’s sales agent and/or principal.”

Equillium, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“October 3, 2023, in connection with the transfer of the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market, the Company was granted an additional 180-day grace period, or until April 1, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company’s failure to regain compliance during this period could result in delisting. The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements, including such actions as a reverse stock split.”

Equillium, Inc. terminated Loan Agreement with Oxford Finance LLC and Silicon Valley Bank valued at total of approximately $6.8 million (effective 2023-05-25).

“On May 25, 2023, Equillium, Inc. (the “Company”), prepaid in full all amounts due and owing under, and terminated, the Loan and Security Agreement dated as of September 30, 2019 (as amended from time to time, the “Loan Agreement”) among Oxford Finance LLC, as collateral agent, the certain lenders, including Oxford Finance LLC and Silicon Valley Bank (the “Lenders”), the Company, and Bioniz Therapeutics, Inc.”

Equillium, Inc. shareholders approved Authorization to Adjourn the Annual Meeting, if Necessary, to Solicit Additional Proxies if there are Not Sufficient Votes in Favor of Proposal 2 at the 2023-05-22 meeting.

“Proposal 4. Authorization to Adjourn the Annual Meeting, if Necessary, to Solicit Additional Proxies if there are Not Sufficient Votes in Favor of Proposal 2. The Company’s stockholders authorized the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were an insufficient number of votes in favor of Proposal 2. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,292,976 1,401,155 569,006 0”

Equillium, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-05-22 meeting.

“Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,948,378 745,510 569,249 0”

Equillium, Inc. shareholders approved Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split at the 2023-05-22 meeting.

“Proposal 2. Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-10, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,178,585 1,520,289 564,263 0”

Equillium, Inc. shareholders approved Election of Directors at the 2023-05-22 meeting.

“Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class II directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. The final voting results are as follows: Name Votes For Votes Withheld Broker Non-Votes Charles McDermott 16,956,930 2,735,613 9,570,594 Bruce Steel 18,638,321 1,054,222 9,570,594 Yu (Katherine) Xu, Ph.D. 19,509,865 182,678 9,570,594”

Equillium, Inc. reported the first quarter ended March 31, 2023 results: revenue $8.9 million, net income $3.9 million, EPS $(0.11) per basic and diluted share.

“nephritis topline data anticipated in 1H 2024, EQUATOR aGVHD interim review anticipated in 2024 First Quarter 2023 Financial Results Revenue for the first quarter of 2023 was $8.9 million and was derived from itolizumab development funding from Ono Pharmaceutical Co, Ltd. (Ono) and amortization of the upfront payment from Ono. Research and development (R&D)”

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 5, 2023, Equillium, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 days, or until October 2, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid pric”

Equillium, Inc. reported the year ended December 31, 2022 results: revenue $15.8 million.

“Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.”

Equillium, Inc. reported the quarter ended December 31, 2022 results: revenue $15.8 million.

“Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.”

Equillium, Inc. shareholders approved Adjournment Proposal at the 2022-12-20 meeting.

“Equillium’s virtual special meeting of its stockholders (the “Special Meeting”), originally scheduled for December 20, 2022 at 12:00 p.m. (Eastern Time), was adjourned, without conducting any business except as described below, to 12:00 p.m. (Eastern Time) on January 10, 2023. The sole proposal presented at the Special Meeting was a proposal to adjourn the Special Meeting, if necessary, to a later date to solicit additional proxies (the “Adjournment Proposal”). Equillium’s stockholders approved the Adjournment Proposal and the voting results are as follows: For Against Abstentions Broker Non-Votes 22,460,787 163,702 5,062 —”

Equillium, Inc. terminated Agreement and Plan of Merger with Metacrine, Inc. (effective 2022-12-23).

“On December 23, 2022, Equillium, Inc. (the “Equillium”) and Metacrine, Inc. (“Metacrine”) agreed to terminate that certain Agreement and Plan of Merger, dated as of September 6, 2022, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of October 26, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among Equillium, Metacrine and the other parties thereto.”

Equillium, Inc. entered into Purchase Agreement with Ono Pharmaceutical Co., Ltd. valued at JPY 3.5 billion (effective 2022-12-05).

“On December 5, 2022, Equillium, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ono Pharmaceutical Co., Ltd. a Japan kabushiki kaisha (“Ono”), pursuant which the Company granted Ono the exclusive right, but not the obligation, to acquire the Company’s rights to itolizumab, a first-in-class monoclonal antibody targeting CD6 (the “Option”). In exchange for the Option, Ono will pay the Company a one-time, non-refundable upfront payment of an amount equal to JPY 3.5 billion, or approximately $26.0 million.”

Equillium, Inc. reported the third quarter ended September 30, 2022 results: net income $13.7 million, EPS $(0.40) per basic and diluted share.

“Net loss for the third quarter of 2022 was $13.7 million, or $(0.40) per basic and diluted share, compared with a net loss of $10.3 million, or $(0.35) per basic and diluted share for the same period in 2021.”

Dr. Barbara Troupin was appointed as Director at Equillium, Inc..

“Effective February 24, 2022, the Board increased the number of directors to nine and appointed Dr. Barbara Troupin, M.D., as a class I director of the Company, effective immediately.”